A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Reason given: The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns
Key facts
- Where
- Barcelona, Madrid, Pamplona, Salamanca, and Valencia, SpainSee the 8 sites
- Phase
- Phase 1
Where in Spain
- Hospital Universitario Vall d'HebronBarcelona, SpainNo longer taking part
- Institut Català d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i ReynalsBarcelona, SpainNo longer taking part
- Hospital Universitario 12 de OctubreMadrid, SpainNo longer taking part
- START Madrid / Hospital Universitario Fundacion Jimenez DiazMadrid, SpainNo longer taking part
- Clínica Universidad de navarraPamplona, SpainNo longer taking part
- Hospital Universitario De SalamancaSalamanca, SpainNo longer taking part
- Hospital Clinico Universitario de ValenciaValencia, SpainNo longer taking part
- Hospital Universitario la FeValencia, SpainNo longer taking part
Trial details
- Who runs it
- Hutchmed
- Trial code
- NCT04764474
- Record updated
- 29 January 2026
- Original description
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.Read full original descriptionShow less
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Inclusion: Subjects may be enrolled in this study only if they satisfy all the following criteria (NOTE: This is not an exhaustive list):; Subjects aged ≥18 years; ECOG performance status ≤ 2; Subjects with advanced relapsed, refractory, or resistant hematological malignancies, as defined below:; Part 1:; Subjects with documented IDH mutation per local or institutional next generation sequence (NGS); Subjects must be refractory to or intolerant of established therapies; Subjects who have received prior IDH inhibitor treatment may be enrolled in the escalation phase; Part 2:; Subjects with documented IDH mutation of any of these subsets: IDH1 (R132C), IDH1 (R132H), IDH (R140Q), and IDH2 (R172K), including co-mutations and any combination thereof per local and institutional NGS; Patients must have received at least 1 prior line of therapy with an IDH inhibitor. An established standard of care with proven benefit for which the patient is eligible, must not be available at the time of enrollment; Patients with AML must not have standard therapeutic options available (including IDH inhibitors where approved) and have the following:; i. Relapsed AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents; ii. Primary refractory AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents; iii. Relapsed/refractory AML that has progressed on prior IDH treatment.
Exclusion: Subjects who received an investigational agent <14 days prior to their first day of study drug administration; Subjects with some current or prior heart conditions; Some subjects with some current or prior gastrointestinal or liver diseases; Part 2 Only: The time since the last dose of prior IDH inhibitor treatment is within 30 days prior to the first day of study drug administration; Subjects with an active severe infection, some treated infections and with an expected or with an unexplained fever >38.3°C during screening visits or on their first day of study drug administration; Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation; Subjects with a known hypersensitivity to HMPL-306 or to any of its excipients; Subjects with presence of second primary malignant tumors within the last 2 years, with the exception of the following, if medically controlled: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and carcinoma in situ of the breast; Subjects taking medications that are known to prolong the QT interval may not be eligible; Subjects with a medical condition, physical examination finding, or clinical laboratory finding that, in the Investigators opinion, contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the subject at high risk from treatment complications; Subjects are not eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):; Subjects who are pregnant or breastfeeding; Subjects with inadequate organ function as defined by the protocol.